Induction ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsTaxoidsChemotherapy, AdjuvantCisplatinCombined Modality TherapyTreatment OutcomeAntineoplastic AgentsRemission InductionPaclitaxelDisease-Free SurvivalCyclophosphamideDoxorubicinNeoadjuvant TherapySurvival AnalysisDrug Administration ScheduleNeoplasm StagingLung NeoplasmsSurvival RateEtoposideCarboplatinAntineoplastic Agents, PhytogenicCytarabineHead and Neck NeoplasmsBreast NeoplasmsPrognosisCarcinoma, Squamous CellCarcinoma, Non-Small-Cell LungDeoxycytidineIfosfamideLeukemia, Myeloid, AcuteVinblastineFluorouracilDaunorubicinMethotrexateNeoplasm Recurrence, LocalNeutropeniaRadiotherapy, AdjuvantDrug Resistance, NeoplasmBleomycinNeoplasm MetastasisChemoradiotherapySalvage TherapyRadiotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaFollow-Up StudiesAntimetabolites, AntineoplasticKaplan-Meier EstimateTransplantation, AutologousGranulocyte Colony-Stimulating FactorVincristineTime FactorsRadiotherapy DosageDose-Response Relationship, DrugOrganoplatinum CompoundsEnzyme InductionMitoxantroneAdenocarcinomaAnthracyclinesIdarubicinHypopharyngeal NeoplasmsInfusions, IntravenousLeukopeniaLeukemia, MyeloidProspective StudiesLaryngectomyTesticular NeoplasmsNeoplasmsMelphalanNasopharyngeal NeoplasmsBridged CompoundsBone NeoplasmsMucositisCamptothecinAntibiotics, AntineoplasticAntibodies, Monoclonal, HumanizedHematopoietic Stem Cell TransplantationDisease ProgressionNeoplasms, Germ Cell and EmbryonalLymphatic MetastasisDose FractionationVindesineThiotepaAsparaginaseRecurrenceClinical Trials as TopicFeasibility StudiesCranial IrradiationLymphoma, Non-HodgkinCell Line, TumorLaryngeal NeoplasmsGerminomaMaximum Tolerated DoseOvarian NeoplasmsConsolidation ChemotherapyNeoplasm, ResidualMesnaTumor Markers, BiologicalClinical Trials, Phase III as TopicRandomized Controlled Trials as Topic